Neo-adjuvant and adjuvant chemotherapy of gastric cancer
Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Michele Orditura(University of Campania "Luigi Vanvitelli"), Gennaro Galizia(Istituto Oncologico Veneto), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Gaetano Aurilio(European Institute of Oncology), Giuseppina Catalano(Unknown), Carmen Belli(European Institute of Oncology), Francesco Giuliani(University of Campania "Luigi Vanvitelli"), Giuseppe Santabarbara(University of Campania "Luigi Vanvitelli")
Cited by 63
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer
|Journal of Clinical Oncology|2015|795